protocols.io

Robust measurement of the real world effectiveness of Tofacitinib for the treatment of Ulcerative Colitis using electronic health records: a protocol and statistical analysis plan

Vivek A. Rudrapatna[1], Atul J. Butte[1]

[1]University of California, San Francisco

dx.doi.org/10.17504/protocols.io.2bqgamw

Vivek A. Rudrapatna
University of California, San Francisco

Upload image
2019

Other

ABSTRACT

The "efficacy-effectiveness gap" refers to the difference between the treatment efficacy as measured by randomized controlled trials (RCTs) and treatment effectiveness as measured in "real world" clinical settings. Prior studies have documented the existance of this gap in a variety of clinical contexts and attributed its existence to a number of factors, including overly restrictive subject inclusion/exclusion criteria in RCTs and differences in treatment efficacy ascertainment.

In this protocol and statistical analysis plan, we document a protocol for a forthcoming study relevant to assessing the efficacy-effectiveness gap of the medication *Tofacitinib* as used to treat Ulcerative Colitis. Specifically, we detail the following:
1) What covariates are needed to compare the real-world effectiveness of Tofacitinib with its efficacy as measured by pivotal clinical trials
2) What approach we propose to extract these covariates from the electronic health records at our institution in a relatively reproducible fashion, balancing accuracy with practicality.
3) How we propose to analyze the data

GUIDELINES

The following criteria is meant to provide guidance to the chart abstractor to facilitate consistent coding. However, these criteria are not absolute, comprehensive or complete; some judgement is required. We advise that this chart extraction be done by a gastroenterologist with IBD experience, ideally also with prior clinical research experience.

- In general, you may have to employ some clinical judgment and your knowledge of the objectives of the study in order to make the proper assessments. For instance, if a patient has an elevated follow-up c-reactive protein but was found at that time to have a concomitant infection, that data must be either be excluded and another datapoint selected (as specified by the protocol to follow) or the column should be annotated as 'NA.' Similarly for situations in which the patient's inflammatory markers rise in the setting of lost insurance. The idea is to capture the data *to the extent that it exists* for the purposes of the study, and if not find a more representative alternative or annotate it as NA. Remember, the statistical models commonly used to analyze the data do not incorporate the *essential* clinical context that only you have access to during the covariate extraction phase.

- All annotations correspond to the period of time when the drug is under consideration or actively being given, not the time of performing the chart review!
    o For instance, age and duration of disease corresponds to the patient's status at the time of initiating treatment
    o If an annotation calls for a follow-up Mayo endoscopic subscore in 2-8 months after treatment initiation and the patient has already discontinued the treatment by month 1, this variable should be annotated as 'NA' rather than by a different value that may correspond to a different treatment regimen.

- Occasionally patients are co-managed between your home institution (i.e. UCSF) and other sites whose clinic notes/records may be accessible via *care everywhere*. Use *request updates* when examining data using this portal and try to take advantage of the availability of multiple independent observations within the electronic health record to maximize the precision of our estimates.

- Using the "magnifying glass" functionality to globally search the medical record can be helpful to find evidence quickly

- Unselect the "default filter" section in order to maximize the records visible to you. Every time you switch between tabs, recheck this section to see that it remains unchecked.

- Note that the *Encounters* and *Notes* tabs contain slightly different elements; both may need to be reviewed for any given purpose.

- When reviewing patient emails, remember to look at the date above the patient "message bubble" as well as the date last read by the patient (below the provider message), and not the date of the encounter associated with the email.

- In general, if the precise day is not known, round down to the first of the month. e.g 2016-10-?? becomes 2016-10-01. If only year known, report January 1st of that year.

- When checking dates, try to use supporting evidence (primary care notes, external GI notes available through *care everywhere* around the time of diagnosis) to confirm the date.

MATERIALS TEXT

- Electronic health record system: this protocol has been tested in the ambulatory context of *Epic*TM software (2017).
- A list of prospective (but not necessarily validated -- this part is embedded into this protocol) medical record numbers corresponding to Inflammatory Bowel Disease patients prescribed Tofacitinib
- HIPAA-compliant server to store all PHI
- IRB approval to identify patient records and handle PHI

SAFETY WARNINGS

In addition to the above relevant to IRB approval and HIPAA compliance, investigators should all be trained or certified in human subjects protection (www.CITIprogram.org)

BEFORE STARTING

- We obtained approval from our institution's IRB (UCSF #18-24588) to enable reidentification of medical records corresponding to IBD patients receiving Tofacitinib. This is strongly recommended for other investigators seeking to use this protocol.

- These steps are somewhat customized for the *Epic* electronic health records at our instution. They may be applicable outside of this system but have not been formally tested and customized as such.

- We obtained access to a HIPAA-compliant server to store protected health information (PHI). This will be necessary for others seeking to use this protocol since the protocol calls for extraction, storage, and analysis of PHI elements.

Validating prospective MRNs using the 'Received Tofacitinib' spreadsheet

1 **Diagnosis**:
{UC, CD, NA}

The best place to unambiguously identify a working diagnosis is a recent colonoscopy done near the time of treatment initiation. In particular, the indication, impression, and recommendations section are often quite useful.

Otherwise, use the diagnosis made at the GI encounter just preceding the prescription and initiation of the drug. This is often helpful because insurance prior authorization of a given medication often requires a clear diagnosis, which is documented in the clinic visit and sent to the payor.

Be mindful of the facts that:
1) the EHR can auto-populate the (sometimes incorrect) diagnosis at the very top and at the first line of the assessment and plan, and
2) copy-forwarded notes can obscure cases of a revised diagnosis (e.g. top of HPI states Ulcerative Colitis, and mid-way indicates Crohn's).

In the latter case, rely on what has been documented in the assessment and plan.

2 **Received Tofacitinib**:
{Y, N, NA}

In general, the presence of a medication order or renewal should be considered insufficient evidence that a drug has actually been taken by the patient.

The best evidence for this is a message from a patient indicating that they've started the drug, or a telephone encounter documenting as such. These often yield precise dates of initiation. Reports from colonoscopies performed to assess treatment response can indicate the date or approximate date of start.

A sequence of clinic notes indicating plans to start the drug followed by a post-initiation visit or endoscopy assessing treatment response can be helpful too. Multiple independent notes from GIs and non-GIs suggesting that the patient started a treatment is good evidence

supporting this.

If the above is unavailable, historical clinical documentation (notes from treating physicians, Indications/Impression/Recommendations sections from endoscopy reports) can be quite helpful.

3   **Initiated to treat IBD**:
{Y, N, NA}

Sometimes patients are initiated on Tofacitinib for reasons that are unrelated to Ulcerative Colitis (for instance, rheumatological or dermatological disorders).

Score as Y if the patient was given the drug for the purposes of treating Ulcerative Colitis (this would most often be decided and ordered by a gastroenterology provider)

Score as N if not. In the setting of UC, this should also include uncommon settings where patients had subtotal colectomies and are trying a steroid-sparing agent before proceeding with completion proctectomy (e.g. these are also scored as an N). Although this logically might be a scenario where one could still assess whether or not it is effective in treating inflammation, monitoring response to treatment is more complex and may not reflect the typical performance of this drug in the setting where it has been formally studied.

If this is the case, these patients can be treated the same as those who did **not** receive the medication; their MRNs should not be transferred to the Table 1 and Efficacy sheets for further analysis (see subsequent sections).

For patients with active symptoms and minimal endoscopic IBD activity, if they were given IBD treatment in the hopes that their symptoms would improve (vs not improve because the symptoms were actually due to something else such as IBS/SIBO), code this as a Y.

If the patient did not even receive the medication (as annotated by the prior variable), code as 'NA.'

4   **Inconsistent Use**:
{Y, N, NA}

Annotate as Y if there is evidence on chart review that the patient was not taking the medication regularly, for example due to personal preferences. Annotate N if no chart evidence to support this. Minimize the use of NA (e.g. if there is no evidence that the patient was the drug inconsistently, annotate as N rather than NA).

Ulcerative Colitis Table 1 Spreadsheet

5   **Gender**:
{M, F, NA}

As ascertained from the clinic note and the demographic face sheet. If there is any evidence of a mismatch (e.g. indicating error or sex-change), score as NA

6   **Date of Disease Onset**:
{YYYY-MM-DD, NA}

Use a combination of the earliest notes in the system (use the *Notes* tab, not the *Encounter* tab), the *Scanned Clinical Documents* tab corresponding to the original clinic referral, and *Care Everywhere* in order to determine as precisely as possible when the patient's disease began. As above, round down for situations where only the month (e.g. 4/1/2018) or the year (1/1/2018) is known. When notes document age of onset rather than date of onset, can select the first day of the next month following the patients birthdate. For instance if the patient is born 2/19/84 and developed the diagnosis at age 10, annotate this as 3/1/94.

For Ulcerative Colitis, the timing of clearly attributable disease onset (rectal bleeding with tenesmus/nocturnal symptoms/weight loss) might have occurred prior to the time of colonoscopic diagnosis. Patients often recall a clear timepoint as to when their symptoms began but sometimes their symptom onset is unclear or not classic for IBD (increased stool frequency without other hallmarks of inflammatory diarrhea as above). In the event of the latter use the date of colonoscopic diagnosis.

7   **Age at Tofacitinib initiation (in years, rounded down)**:
{Integer, NA}

To be calculated based on the patient's birthdate and the date of Tofacitinib initiation. Be wary of using the age reported in clinic notes as the basis of this – these notes are often copy-forwarded and incorrect. Use the birthdate and date of drug initiation.

8 **Disease duration at time of Tofacitinib initiation (# months/12)**:
{Rational Number, NA}

This field requires a greater degree of precision than the prior field assessing age. If chart review does not yield an exact day, use the earliest compatible day at which treatment could have been started. For instance if the patient writes an email indicating that he started treatment about 2 weeks prior to that date of communication, use 14d prior to that date.

Then, calculate disease duration in fractional units of years based on dividing the number of months with disease by 12. In other words, if the patient had the disease for 8 years and 3 months, reports 8 + 3/12 here. This should be reported as a rational number (if using Excel, it should calculate this for you if you use the '=' prefix).

9 **Disease extent at time of Tofacitinib initiation**:
{1, 2, 3, NA}

1 = Proctitis or Proctosigmoiditis
2 = Left-sided colitis (extends to but not beyond the splenic flexure
3 = Extensive or pan-ulcerative colitis (anything extending beyond the splenic flexure)

Prioritize Sigmoidoscopic/Colonoscopic data prior to Tofacitinib initiation as the gold standard to ascertain this (e.g. how far the disease had spread by the time Tofa had started). This should reflect the extent of underlying anatomical territory that has ever been endoscopically involved up to this timepoint, not just what is currently involved (e.g. if the rectum appears spared on a follow-up exam and the patient is on treatments including steroid enemas this should not affect the categorization of the disease extent).

If Sigmoidoscopy reveals disease through the extent of the exam, can also use supportive imaging data as needed to judge extent. If this is unavailable, acceptable to use note-based documentation. Be aware that imaging-based extent can often overcall extent compared to endoscopy and histology.

Under scenarios of discrepant endoscopic findings (endoscopic extent involving the transverse colon in one and not in another), annotate this field by the maximum documented extent.

It is acceptable to use data from within 6 months of the start to retroactively assess disease extent. For instance, if a clinic note indicates left-sided colitis but imaging and surgical pathology within 6 months indicate extensive/pancolitis, annotate as the latter. The assumption is that sampling error and chronic disease progression is a more likely explanation for prior misclassification than the possibility that the drug caused an acute and significant extension of anatomic involvement).

Score this based on endoscopic rather than histologic disease extent. The rationale for this is that the disease extent classification in the trials was more likely to use gross endoscopic extent rather than histologic extent. This need not fall strictly within the same strict time windows as the Mayo Score data.

10 **Baseline Mayo stool frequency subscore**:
{0, 1, 2, 3, NA}

We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. **Month -6 to Month 0**). The idea here is to attempt to match our patient cohort with that of the clinical trials.

The rationale for using such a broad time window is that endoscopic scheduling and insurance approval for a planned drug, among other factors, can create a lag between the time of Mayo endoscopic subscore data availability and treatment initiation. So we are allowing the other Mayo subscore variables to capture data from the same time window.

Per the OCTAVE supplemental data protocol (Appendix 1, page 80):
0: Normal number of bowel movements for this patient
1: 1 to 2 bowel movements more than normal
2: 3 to 4 bowel movements more than normal
3: 5 or more bowel movements more than normal

The above data is sometimes documented in the chart by absolute frequency of bowel movements. Per FDA guidance a bowel movement "is defined as a trip to the toilet when the patient has either a bowel movement, or passes blood alone, blood and mucus, or mucus only." Therefore, stool frequency should incorporate toilet trips when there is passage of any liquid or solid content through the anus, not limited only to feces.

If the stool frequency is reported as a relative increase over baseline, no ascertainment of absolute baseline frequency is required. However, if stool frequency is reported as an absolute frequency, the chart reviewer must make every effort to identify a baseline stool frequency from the chart. This can be identified from anywhere within full record, including timepoints before or after Tofacitinib use. We recommend

using the global search functionality to look for keywords like: "baseline" "normal" "1-2" "2-3" "stools" "bowel movements" etc.

If the notes do not explicitly mention "baseline" but do indicate a stool frequency of between 1-3 bowel movements daily in any context (e.g. other treatments such as steroids), treat this number as the baseline. The justification for this is that population-based studies have suggested that up to 3 bowel movements daily can be considered normal.
If the patient has baseline constipation during periods of quiescence and returns to use of stool softeners/laxatives, can impute this field to 0 (e.g. assume use of stool softeners to achieve 1 bowel movement daily).

If no "baseline" nor approximate baseline is mentioned, a baseline of 3 bowel movements daily can be imputed at the chart reviewers discretion. This selection would not be expected to significantly affect the study results since the analysis will involve the paired differences in Mayo scores. If this is done an additional indicator variable denoting that this was performed should be added to the data collection spreadsheet.

When dealing with numeric ranges of bowel movements, calculate the score based on the minimum increase in stool frequency compatible with the range. For instance, if a patient has 1-2 bowel movements at baseline, and is currently having 5-6 during the morning and 2-3 over the rest of the day, this would be a difference between (1 to 2) and (7 to 9), corresponding to a minimum increase of 6 bowel movements above baseline (e.g. 1 to 7 is 6 above baseline, 2 to 9 is 7 above baseline, hence take the minimum). Therefore, this is scored as a '3' based on the above rubric.

In the event that multiple such subscores exist within this window, we use the following algorithm:
1. Select the stool frequency subscore occurring closest in time to the date of treatment failure
2. If no treatment failure and a colonoscopy was performed within this period, select the stool frequency subscore occurring closest in time to the date of the colonoscopy
3. If no colonoscopy was performed in this period, select the highest available subscore within this 6 month window.

The rationale for picking the highest score within the window is that some assessments may be masked by concomitant therapy (e.g. steroids) which are somewhat harder to ascertain from the EHR.

As mentioned in the top section 'Guidelines': exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable.

Score this field as NA if it is not satisfactorily identified.

11   Baseline Mayo rectal bleeding subscore:
{0, 1, 2, 3, NA}

We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. **Month -6 to Month 0**). The idea here is to attempt to match our patient cohort with that of the clinical trials.

The rationale for using such a broad time window is that endoscopic scheduling and insurance approval for a planned drug, among other factors, can create a lag between the time of Mayo endoscopic subscore data availability and treatment initiation. So we are allowing the other Mayo subscore variables to capture data from the same time window.

Per the OCTAVE supplemental data protocol (Appendix 1, page 80):
0: No blood seen
1: Streaks of blood with stool less than half the time
2: Obvious blood with stool most of the time
3: Blood alone passes

This part of the score has been recognized by the FDA to be suboptimal (FDA CDER Draft Guidance, Aug 2016) for multiple reasons including the fact that it is a "double-barreled" question (e.g. asks about both amount and frequency of blood). Presumably as a measure to correct the frequency problem, the Pfizer Protocol indicates that this should be scored "the most severe bleeding of the day."

We have adopted the following pragmatic strategy:
1) If data of bleeding severity is available, then score based on this as follows:
    o If there is clear documentation of no bleeding, score as 0.
    o If there is clear documentation of episodes where only blood passes, score this as a 3.
    o If there is bleeding but the amount is vague (e.g. "some") then code this as a 1.5.
    o Otherwise if there is a clear indication of degree of bleeding, use 1 or 2 as appropriate.
2) If severity data is not available but the frequency data is, then scoring using this data and the OCTAVE metric above can be performed at the discretion of the chart abstractor.

If there exist multiple datapoints within this 6-month time window, use the approach as outlined in the stool frequency section. If multiple

datapoints around the same time suggest slightly different degrees of bleeding, select the most severe degree of bleeding. If the note indicates blood 50% of the time, score as 1.5.

12 **Baseline Mayo PGA subscore**:
{0, 1, 2, 3, NA}

We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. **Month -6 to Month 0**). The idea here is to attempt to match our patient cohort with that of the clinical trials.

The rationale for using such a broad time window is that endoscopic scheduling and insurance approval for a planned drug, among other factors, can create a lag between the time of Mayo endoscopic subscore data availability and treatment initiation. So we are allowing the other Mayo subscore variables to capture data from the same time window.

Per the supplemental data:
0: Normal
1: Mild disease
2: Moderate disease
3: Severe disease

Per the Pfizer protocol used for the OCTAVE trials, this score "acknowledges the three other criteria, the patient's recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the patient's performance status."

This score ideally should reflect a **dynamic**, "real-time" assessment of disease activity (e.g. evidence of ongoing inflammation cauing symptoms that is in principle modifiable by medication). This is in contrast to annotations of severe disease based on, for example, the history of multiple prior treatment failures.

A good place to identify the physician's global assessment (PGA) is the end of colonoscopy reports, where patients are commonly characterized as "mild" or "severe" independent of scoring using the Mayo endoscopic score. Other sources of the PGA include the Assessment and Plan of clinic notes, or appeal letters to insurance; the former is preferable because it 1) is written by the attending physician, rather than fellows/residents in clinic, and 2) appeal letters to insurance may be at risk of bias.

In the event that multiple such subscores exist within this window, use the same approach as detailed in the stool frequency section.

As mentioned in the top section 'Guidelines': exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable.

13 **Baseline Mayo endoscopic subscore**:
{0, 1, 2, 3, NA}

We are attempting to capture this Mayo subscore within 6 months of the date of Tofacitinib initiation (e.g. **Month -6 to Month 0**). The idea here is to capture the severity of disease as well as the fact that this data was actively used to guide the decision to initiate Tofacitinib. Unlike the OCTAVE trials which required a staging colonoscopy to be performed within 1 week of randomization, we allow a 6 month lag here to account for delays in insurance approval and initiation.

Use the endoscopic impression of disease – histological data can be supportive but in the trials the primary ascertainment was by centrally-read endoscopy alone. If the endoscopist explicitly reports a Mayo endoscopic subscore than report this in the field. If he or she does not, score it using the descriptive language from the report as they map to the fields below, and annotate based on the most severely affected segment. If the colon was mostly quiet but there was an ulcer in the rectum, this would be scored as a 3.

Per the OCTAVE supplemental data protocol (Appendix 1, page 80), the modified Mayo endoscopic subscore as defined below. Underlined items and in parenthesis are my emphasis to facilitate distinguishing categories.

0: Normal or inactive disease (this includes chronic scaring, pseudopolyps)
1: Mild disease -- erythema, decreased vascular pattern
2: Moderate disease -- marked erythema, lack of vascularity, any friability, erosions
3: Severe disease – spontaneous bleeding, ulceration(ulcers are defined by the presence of granulation tissue)

If there exist multiple datapoints within this time window, select the latest one up to the time of treatment failure, if it occurred.

If the patient is subsequently found to have superinfection including CMV that may influence the results of the endoscopy, consider excluding these results from the data used to annotate this field.

If the patient is on any glucocorticoid at the time this assessment is done, it's okay to report whatever was found here (as opposed to mark

as 'NA'); we are separately assessing corticosteroid use in a different variable.

14 **Baseline c-reactive protein**:
{Rational number, NA}

As with the Mayo Endoscopic subscore, use the latest available C-Reactive Protein within the 6 months preceding the date of Tofacitinib initiation. Please use the date of the lab draw to make your assessment. If it is unavailable strictly within this 6 month antecedent window, score as NA. If the lab is reported under the quantifiable limit, report '0'. If it is over the quantifiable limit, report the threshold of quantification.

Be careful that different labs use different units! All values should be reported in mg/L, not mg/dL.

15 **Baseline fecal calprotectin**:
{Rational number, NA}

As with the Mayo Endoscopic subscore, use the latest available Fecal Calprotectin within the 6 months preceding the date of Tofacitinib initiation. Please use the date of the lab draw to make your assessment. If it is unavailable strictly within this 6 month antecedent window, score as NA. If the lab is reported under the quantifiable limit, report '0'. If it is over the quantifiable limit, report the threshold of quantification.

16 **Baseline glucocorticoid use**:
{Y, N, NA}

The rationale underlying this variable is to give some indication as to if patients who were on steroids are systematically different in terms of response (or any other variable of interest) compared to those who were not.

The OCTAVE trials employed essentially stable glucocorticoid dosing during the induction phase (Table 3, page 40 of the supplemental protocol) at a max entry dose of 25mg prednisone/9mg budesonide, and mandatory tapering (Table 2, page 646) during the maintenance phase. IV and rectal corticosteroids were prohibited from use over the course of the trial.

However, since patients in routine clinical practice are regularly on these co-therapies and do not follow protocolized tapering schedules, this variable will simply capture all patients who received any systemic glucocorticoid (including Prednisone, Prednisolone, Budesonide) either intravenously or orally at the time of Tofacitinib initiation. We are not including rectal steroids here because of generally low systemic absorption unlikely to significantly confound the likelihood of declaring treatment failure or follow-up Mayo score.

Use the clinic or consult note just before and after initiation on the drug as well as communication via phone or email during this period as the source of your data. If the data does not exist in a satisfactory way, record NA.

17 **Previous treatment with TNF antagonist**:
{Y, N, NA}

Use the clinic notes, *Care Everywhere* GI notes if they exist, and the "magnifying glass" global search functionality to determine if the patient has previously received any of the following TNF inhibitors -- Infliximab, Adalimumab, Golimumab, Certolizumab -- specifically for the purposes of treating IBD (e.g. not for a rheumatological or dermatological disorder).

Score as Y if the patient has previously been treated with a TNF antagonist
Score as N if patient has never previously been treated with a TNF antagonist

18 **History of TNF antagonist failure**:
{Y, N, NA}

Use the clinic notes, *Care Everywhere* GI notes if they exist, and the "magnifying glass" global search functionality to determine if the patient has failed any of the following TNF inhibitors -- Infliximab, Adalimumab, Golimumab, Certolizumab -- specifically for the purposes of treating IBD (e.g. not for a rheumatological or dermatological disorder).

As in the OCTAVE protocol and accompanying NEJM publication, the history of treatment failure is as determined by the treating clinician. For Tofacitinib, the trial withdrawal criteria included serious infections, significant abnormal labs, adverse events, surgery, new therapy for UC, or at the patient's request.

Score as Y if the patient has previously failed treatment with a TNF antagonist
Score as N if patient has never previously failed treatment with a TNF antagonist

19 **History of oral glucocorticoid failure**:
{Y, N, NA}

Use the clinic notes, *Care Everywhere* GI notes if they exist, and the "magnifying glass" global search functionality to determine if the patient has failed any oral glucocorticoid (e.g. budesonide, prednisone, prednisolone). If a patient has been hospitalized for an IBD flare and receives IV steroids (e.g. methylprednisolone) then score this as 1.

Refer to the section History of TNF antagonist failure for additional guidance.

Score as 0 if patient has never previously failed treatment with a Glucocorticoid
Score as 1 if the patient has previously failed treatment with a Glucocorticoid

There may be a questions raised in this section related to patients receiving lower than typical doses of prednisone, having a partial response to therapy, or responding but in the setting of simultaneous immunosuppressant co-therapy (so difficult to tell which was responsible for the improvement). In general would tend to err on the side of no failure rather than coding this as NA (esp if not unambiguous documented as such).

20 **History of immunosuppressant failure**:
{Y, N, NA}

Use the clinic notes, *Care Everywhere* GI notes if they exist, the presence of thiopurine metabolite laboratories (e.g. 6-Thioguanine), and the "magnifying glass" global search functionality to determine if the patient has failed any 'immunosuppressant' (e.g. Azathioprine, 6-Mercaptopurine, Methotrexate, Cyclosporine A, Tacrolimus).

Refer to the section History of TNF antagonist failure for additional guidance.

If the patient was previously on this drug in combination with another (e.g. biologic) and was deemed to have failed that regimen, score as Y.

Score as Y if the patient has previously failed treatment with an Immunosuppressant
Score as N if patient has never previously failed treatment with an Immunosuppressant

Ulcerative Colitis Effectiveness Spreadsheet

21 **Date of Tofacitinib initiation**:
{YYYY-MM-DD, NA}

As above, the best evidence to ascertain this is a message from a patient indicating that they've started the drug, or a telephone encounter documenting as such. These often give relatively precise dates of initiation.

If there is a sequence of clinical notes (before and after) that are consistent with initiation, these can be used in combination with the date of medication orders (listed within a medication order) to find a more precise date of initiation.

If dealing with older notes where supporting data (e.g. patient messages, medication orders) are unavailable, then document use the month (or less commonly, the year) and report a "rounded down" date (e.g. 2018-05-01).

Rarely, there are patients who have been on a drug for multiple continuous periods of time (e.g. initially on a clinical trial then again later, or patients who stop due to possible drug reaction and subsequently restart). In these scenarios, prioritize the longest period of sustained use. If there are multiple, equally long on-off periods, select the most recent period with well-defined start and end dates. If this is not possible because the patient starts and stops a drug erratically or does not use it daily, score this as NA and annotate the "inconsistent use" column accordingly.

22 **Date of last known use of Tofacitinib (date of censorship)**
{YYYY-MM-DD, NA}

This date corresponds to the last observed date that the drug was observed being used (from the standpoint of survival analysis). This could be the date of discontinuation, the last date of any available evidence (e.g. contact with our clinic or other accessible gastroenterologists), date of surgery, or date of death. If patients are still on the drug as of the date of the record review, this would be the recorded date (and they would be considered administratively censored).

As before, the best evidence to get this comes from a patient email indicating that they've stopped the drug, a colonoscopy report with the recommendation to stop the treatment given futility, or a clinician writing to a patient indicating to a patient that they should stop the drug.

23 **Status at date of last use (censorship status)**

{0, 1, 2, 3, NA}

Score as 1 if the treatment has been deemed futile. This could be for any reason – lack of effectiveness or adverse outcome/intolerance. This could be decided by either the patient or the physician (or both).

Score as 0 (administratively censored) if the 'implicit/true time of treatment failure' is longer than the time under observation. For instance, if the patient is still on a drug as of the date of a chart review, or the patient discontinues the drug due to loss of insurance coverage, their latent 'survival' time is longer than the time under observation (e.g. under different circumstances with greater observation time and guaranteed insurance, the measured time to treatment failure would be longer than what was measured here). Here, the loss of insurance coverage is being treated as MCAR (missing completely at random).

Score as a 2 if the patient was lost to follow-up defined as the absence of any data relevant to IBD status and continued treatment anywhere in the chart (including *Care Everywhere*) for 1 year. This category is a stand in for any status where the investigator must assess on a case by case basis whether the event can be justifiably be understood as resulting in data MCAR vs other types of missingness.

Score as 3 if the patient underwent a true competing event (e.g. all-cause mortality) that fundamentally precludes the observation of interest (e.g. treatment survival time).

If a patient undergoes surgery because a treatment is deemed a failure, score this as a 1. If the patient undergoes surgery due to longstanding fibrostenotic strictures and the drug is not resumed after surgery (with notes suggesting the absence of evidence that the treatment was a failure), score this as a 0.

24   **Follow-up Mayo stool frequency subscore**:
{0, 1, 2, 3, NA}

We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the stool frequency subscore *within the window from month 2 through to month 8 after treatment initiation*.

We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).

Per the OCTAVE supplemental data protocol (Appendix 1, page 80), this subscore is to be scored using the following ordinal scale:
0: Normal number of bowel movements for this patient
1: 1 to 2 bowel movements more than normal
2: 3 to 4 bowel movements more than normal
3: 5 or more bowel movements more than normal

Per FDA guidance a bowel movement "is defined as a trip to the toilet when the patient has either a bowel movement, or passes blood alone, blood and mucus, or mucus only." Therefore, stool frequency should incorporate toilet trips when there is passage of any liquid or solid content through the anus, not limited only to feces.

If the stool frequency is reported as a relative increase over baseline, no ascertainment of absolute baseline frequency is required. However, if stool frequency is reported as an absolute frequency, the chart reviewer must make every effort to identify a baseline stool frequency from the chart. This can be identified from anywhere within full record, including timepoints before or after Tofacitinib use. We recommend using the global search functionality to look for keywords like: "baseline" "normal" "1-2" "2-3" "stools" "bowel movements" etc.

If the notes do not explicitly mention "baseline" but do indicate a stool frequency of between 1-3 bowel movements daily in any context (e.g. other treatments such as steroids), treat this number as the baseline. The justification for this is that population-based studies have suggested that up to 3 bowel movements daily can be considered normal.
If the patient has baseline constipation during periods of quiescence and returns to use of stool softeners/laxatives, can impute this field to 0 (e.g. assume use of stool softeners to achieve 1 bowel movement daily).

If no "baseline" nor approximate baseline is mentioned, a baseline of 3 bowel movements daily can be imputed at the chart reviewers discretion. This selection would not be expected to significantly affect the study results since the analysis will involve the paired differences in Mayo scores. If this is done an additional indicator variable denoting that this was performed should be added to the data collection spreadsheet.

When dealing with numeric ranges of bowel movements, calculate the score based on the minimum increase in stool frequency compatible

with the range. For instance, if a patient has 1-2 bowel movements at baseline, and is currently having 5-6 during the morning and 2-3 over the rest of the day, this would be a difference between (1 to 2) and (7 to 9), corresponding to a minimum increase of 6 bowel movements above baseline (e.g. 1 to 7 is 6 above baseline, 2 to 9 is 7 above baseline, hence take the minimum). Therefore, this is scored as a '3' based on the above rubric.

In the event that multiple such subscores exist within this window, we use the following algorithm:
1. Select the stool frequency subscore occurring closest in time to the date of treatment failure
2. If no treatment failure and a colonoscopy was performed within this period, select the stool frequency subscore occurring closest in time to the date of the colonoscopy
3. If no colonoscopy was performed in this period, select the highest available subscore within this 6 month window.

The rationale for picking the highest score within the window is that some assessments may be masked by concomitant therapy (e.g. steroids) which are somewhat harder to ascertain from the EHR.

As mentioned in the top section 'Guidelines': exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable.

Score this field as NA if it is not satisfactorily identified.

25   **Follow-up Mayo rectal bleeding subscore**:
{0, 1, 2, 3, NA}

We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the rectal bleeding subscore *within the window from month 2 through to month 8 after treatment initiation*.

We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).

Per the OCTAVE supplemental data protocol (Appendix 1, page 80):
0: No blood seen
1: Streaks of blood with stool less than half the time
2: Obvious blood with stool most of the time
3: Blood alone passes

This subscore has been acknowledged by the FDA to be imperfect (FDA CDER Draft Guidance, Aug 2016) for multiple reasons including the fact that it is a "double-barreled" question (e.g. simultaneously assesses both amount and frequency of blood). Presumably as a measure to correct the frequency problem, the Pfizer protocol indicates that this should be scored based on "the most severe bleeding of the day."

We have adopted the following pragmatic strategy:
1) If data of bleeding severity is available, then score based on this as follows:
    o If there is clear documentation of no bleeding, score as 0.
    o If there is clear documentation of episodes where only blood passes, score this as a 3.
    o If there is bleeding but the amount is vague (e.g. "some") then code this as a 1.5.
    o Otherwise if there is a clear indication of degree of bleeding, use 1 or 2 as appropriate.
2) If severity data is not available but the frequency data is, then scoring using this data and the OCTAVE metric above can be performed at the discretion of the chart abstractor.

If there exist multiple datapoints within this 6-month time window, use the approach as outlined in the stool frequency section. If multiple datapoints around the same time suggest slightly different degrees of bleeding, select the most severe degree of bleeding. If the note indicates blood 50% of the time, score as 1.5.

26   **Follow-up Mayo PGA subscore**:
{0, 1, 2, 3, NA}

We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal

assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the physician's global assessment within the window *from month 2 through to month 8 after treatment initiation*.

We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).

The scoring system is as follows (with acceptable phrasing in parenthesis):
0: Normal ("in remission", "in clinical remission")
1: Mild disease
2: Moderate disease
3: Severe disease

Per the Pfizer protocol used for the OCTAVE trials, this score "acknowledges the three other criteria, the patient's recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the patient's performance status."

This score ideally should reflect a **dynamic**, "real-time" assessment of disease activity (e.g. evidence of ongoing inflammation cauing symptoms that is in principle modifiable by medication). This is in contrast to annotations of severe disease based on, for example, the history of multiple prior treatment failures.

A good place to identify the physician's global assessment (PGA) is the end of colonoscopy reports, where patients are commonly characterized as "mild" or "severe" independent of scoring using the Mayo endoscopic score. Other sources of the PGA include the Assessment and Plan of clinic notes, or appeal letters to insurance; the former is preferrable because it 1) is written by the attending physician, rather than fellows/residents in clinic, and 2) appeal letters to insurance may be at risk of bias.

In the event that multiple such subscores exist within this window, use the same approach as detailed in the stool frequency section.

As mentioned in the top section 'Guidelines': exclude any stool frequency confounded by the presence of a concomitant infection or treatment interruption. The exception to this rule is the presence of concomitant steroids. In this case, report the stool frequency; we will also capture the presence of steroid use in a separate indicator variable.

27   Follow-up Mayo endoscopic subcore
{0, 1, 2, 3, NA}

We are collecting the components of the Mayo score in order to allow us to closely mimic the primary endpoints of the OCTAVE trials. These endpoints are intended to measure the proportion of patients who respond to maintenance therapy at the 1 year time point. At our institution we do not protocolize the timing of clinic follow-up and different clinicians have different practices. However, many clinicians tend to formal assess response to therapy by month ~3 for Ulcerative Colitis, and occasionally month ~4-6 especially in individuals who have shown partial benefit within the first few months. However, scheduling in routine clinical contexts can be imprecise. Many patients live far away, sometimes in other states. Due to these considerations, including personal and administrative delays in scheduling, insurance approval etc., we are collecting the endoscopic subscore within the window *from month 2 through to month 8 after treatment initiation*.

We considered a longer follow-up time to more closely mimic the 1 year time point studied in OCTAVE Sustain but pilot studies suggested that endoscopic and clinical assessment at that time was less common than at earlier time points (and therefore might result in more missing data).

Use the endoscopic impression of disease, and do not use any histological data to make this annotation. It is important to try to score this as the endoscopist would have scored it without introducing your own interpretation. Some endoscopists use a formal scoring system built into Endopro, whereas others use descriptive language to characterize the severity of the disease. In the event of the latter, use the words mapping to the **most** severe endoscopic category to make your annotation.

Per the Supplemental Data form, use the modified Mayo endoscopic subscore as defined below. The unique terms that distinguish one category from another are underlined.

0: Normal or <u>inactive</u> disease (this includes chronic scaring, pseudopolyps)
1: Mild disease -- erythema, decreased vascular pattern
2: Moderate disease -- marked erythema, lack of vascularity, <u>any friability</u>, <u>erosions</u>
3: Severe disease – <u>spontaneous bleeding</u>, <u>ulceration</u>(ulcers are defined by the presence of granulation tissue)
If there exist multiple datapoints within this time window, select the latest one up to the time of treatment failure, if it occurred.

If the patient is subsequently found to have superinfection including CMV that may influence the results of the endoscopy, consider excluding these results from the data used to annotate this field.

If the patient is on any glucocorticoid at the time this assessment is done, it's okay to report whatever was found here (as opposed to mark as 'NA'); we are separately assessing corticosteroid use in a different variable.

28   **Follow-up c-reactive protein**:
{Rational number, NA}

As with the Mayo Endoscopic subscore, use the latest available C-Reactive Protein within the 6-12 month window following Tofacitinib initiation. If it is unavailable strictly within this window, score as NA. If the lab result is reported under the quantifiable limit, report '0'. If it is over the quantifiable limit, report the threshold of quantification.

Be careful that different labs use different units! We want mg/L, not mg/dL.

If the patient is on any glucocorticoid at the time this assessment is done, it's okay to report whatever was found here (as opposed to mark as 'NA'); we are separately assessing corticosteroid use with a different variable.

29   **Follow-up fecal calprotectin**:
{Rational number, NA}

As with the Mayo Endoscopic subscore, use the latest available Fecal Calprotectin within the 6-12 month window following Tofacitinib initiation. If it is unavailable strictly within this window, score as NA. If the lab result is reported under the quantifiable limit, report '0'. If it is over the quantifiable limit, report the threshold of quantification.

If the patient is on any glucocorticoid at the time this assessment is done, it's okay to report whatever was found here (as opposed to mark as 'NA'); we are separately assessing corticosteroid use with a different variable.

30   **Follow-up glucocorticoid use**:
{0, 1, NA}

Even though this data point does not exist within the clinical trials, it is an important measurement to capture in order to properly interpret the follow-up subscore data.

The rationale underlying this variable is to give some indication as to if patients who were on steroids are systematically different in terms of response (or any other variable of interest) compared to those who were not.

The OCTAVE trials employed essentially stable glucocorticoid dosing during the induction phase (Table 3, page 40 of the supplemental protocol) at a max entry dose of 25mg prednisone/9mg budesonide, and mandatory tapering (Table 2, page 646) during the maintenance phase. IV and rectal corticosteroids were prohibited from use over the course of the trial.

However, since patients in routine clinical practice are regularly on these co-therapies and do not follow protocolized tapering schedules, this variable will simply capture all patients who received any systemic glucocorticoid (including Prednisone, Prednisolone, Budesonide) either intravenously or orally at the time of follow-up. We are not including rectal steroids here because of generally low systemic absorption unlikely to significantly confound the likelihood of declaring treatment failure or follow-up Mayo score.

Use the clinic or consult note just before and after initiation on the drug as well as communication via phone or email during this period as the source of your data. If the data does not exist in a satisfactory way, record NA.

31   **Other co-therapy**:
{0, 1, NA}

This is intended to be an indicator variable for whether or not the patient is on any other concurrent therapy that would be expected to positively confound the treatment effect of tofacitinib (e.g. golimumab, vedolizumab, steroid enemas, 5-ASA, hyperbaric oxygen, VSL #3, curcumin).

Mark this as 1 if the patient is on any other IBD treatments that might be expected to mask the isolated effect of Tofacitinib from a treatment standpoint. Do not include treatments that treat other non-IBD conditions (e.g. PPI). If the patient is on an immunomodulator with systemic action based on prescription by another provider (e.g. rheumatologist) mark this field as '1' only if this agent has been shown in prospective clinical trials to reduce gastrointestinal inflammation, 0 otherwise.

| Statistical Analysis Plan |

32   **Primary endpoints**:
1) Time to treatment failure

2) Proportion of patients without treatment failure at 1 year (*real-world effectiveness rate*)

Null hypothesis: The probability of incident users of Tofacitinib without treatment failure at 1 year in the 'real-world' setting is equal to the probability of remission (total Mayo score of ≤2, with no subscore >1 and a rectal bleeding subscore of 0) at week 52 as reported by the OCTAVE investigators (Sandborn et al. 2017)

Alternative hypothesis: The probability of incident users of Tofacitinib without treatment failure at 1 year in the 'real-world' setting is **not equal** to the probability of remission (total Mayo score of ≤2, with no subscore >1 and a rectal bleeding subscore of 0) at week 52 as reported by the OCTAVE investigators (Sandborn et al. 2017)

Sample size considerations: Because this represents a uncontrolled study of observational data, no power calculation was performed. Preliminary data at our institution (UCSF) as of May 2019 suggested up to ~120 IBD patients who had been prescribed Tofacitinib.

Analysis of primary endpoints:
The time to treatment failure will be estimated using the Kaplan-Meier estimator; survival times corresponding to the 25th, 50th, and 75th percentiles of treatment failure will be calculated.

The analysis set will be restricted to individuals who individuals with observation time ≥ 1 year, and the counts of individuals with and without treatment failure at 1 year will be tabulated.

Counts corresponding to Sandborn et al. 2017 will be computed as follows: The total proportion of responders will be calculated as the product of the probability of achieving *clinical response* (a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1) at week 8 by the probability of achieving *remission* at week 52. The total number of patients assigned to the active arm of OCTAVE Sustain who achieved remission at week 52 will be divided by the aforementioned product to determine an effective sample size for the week 52 assessment of clincal remission.

These counts will be used to perform a Fisher's exact test.

Analysis of patient demographics:
Patients with greater with observation time ≥ 1 year will be tabulated by baseline demographic characteristics measured here and compared to the summary statistics reported in Table 1 of Sandborn et al. 2017. Proportions and categorical variables will be compared by Fisher's exact test, means will be compared by 1-sample t-test, and medians compared by 1-sample Wilcoxon test. No corrections for multiple testing will be performed unless otherwise specified.

Quality Control: Exploratory data analysis will be performed to confirm accuracy of data entry and identify outlying observations.

Missing data: Missing data will be handled by Multiple Imputation using Chained Equations using the Fully Conditional Specification using at least 20 chains and 10 interations. The quality of the imputations will be assessed via assessment of Markov Chain Monte Carlo trace plots and univariate and bivariate distributions of imputed values. Results will be assessed using different imputation models .

Software: All analyses will be performed in the *R* programming environment with the following packages representing a non-exclusive list: 'data.table', 'survival', 'survminer', 'readxl', 'tidyverse', 'scales', 'binom', 'ggplot2', 'lubridate', 'RMarkdown', 'MICE', 'caret'

Sensitivity analysis:
1) The hypothesis test comparing the real-world effectiveness rate with that of the OCTAVE Sustain trial will be repeated using less stringent W52 endpoints to account for the possibility that the real-world determination of treatment failure may be less stringent than that of the OCTAVE primary endpoint.
2) The data will be analyzed in a Bayesian framework with posterior probability distributions calculated using the following prior Beta distributions: Jeffrey's Prior, prior distribution corresponding to the patient counts from the OCTAVE Sustain trial, and a beta distribution with median equal to 1/3 and 0.05 quantile equal to 0.1.

Exploratory analyses/endpoints: An exploratory analysis will include the following:
1) Proportion of real-world patients who would have qualified for the randomized clinical trial based on all Inclusion/Exclusion criteria
2) Proportion of real-world patients who would have qualified for the randomized clinical trial based on baseline total Mayo Score
3) Proportion of real-world patients meeting the primary endpoint of clinical remission and selected secondary endpoints as defined and published by the OCTAVE investigators
4) Other machine learning algorithms (Random Forests, Support Vector Machines, Quadratic Discriminant Analysis, Ensemble Models, penalized logistic regression) will be explored to determine their accuracy in predicting treatment response using baseline and early follow-up covariates